AVTRNYSELaboratory Analytical InstrumentsFiscal year ends December 31
Avantor, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.29−0.13 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $11.03B
- P/E (TTM)
- –
- Dividend yield
- –
Avantor, Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | – | – | – | – | – | – | – | – | – | – | – | $2.43B | – | – |
| Americas | – | – | – | – | – | – | – | – | – | – | – | $4.12B | – | – |
| Bioscience Production | – | – | $2.15B | $2.17B | $2.18B | $2.17B | $2.17B | $2.15B | $2.17B | $2.17B | $2.23B | – | – | – |
| Laboratory Solutions | – | – | $4.40B | $4.41B | $4.48B | $4.52B | $4.61B | $4.67B | $4.65B | $4.69B | $4.74B | – | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary | $3.44B | $3.45B | $3.45B | $3.48B | $3.54B | $3.56B | $3.62B | $3.64B | $3.64B | $3.65B | $3.72B | $4.61B | 52.4% | -2.9% |
| Third-party | $3.12B | $3.10B | $3.10B | $3.10B | $3.12B | $3.12B | $3.17B | $3.18B | $3.18B | $3.22B | $3.25B | $3.86B | 47.6% | -0.1% |
| Equipment & instrumentation | – | – | – | – | – | – | – | – | – | – | $928.00M | $941.50M | – | – |
| Services & specialty procurement | – | – | – | – | – | – | – | – | – | – | $963.50M | $941.10M | – | – |
By region
From the segment and revenue-disaggregation notes of Avantor's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.